Production (Stage)
Structure Therapeutics Inc.
GPCR
$24.55
-$0.10-0.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.44M | 13.57M | 13.24M | 11.27M | 11.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.31M | 47.06M | 45.84M | 33.32M | 32.02M |
| Operating Income | -56.31M | -47.06M | -45.84M | -33.32M | -32.02M |
| Income Before Tax | -46.74M | -36.34M | -33.89M | -25.98M | -26.01M |
| Income Tax Expenses | 98.00K | 136.00K | 92.00K | 53.00K | 29.00K |
| Earnings from Continuing Operations | -46.83M | -36.48M | -33.98M | -26.03M | -26.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.83M | -36.48M | -33.98M | -26.03M | -26.04M |
| EBIT | -56.31M | -47.06M | -45.84M | -33.32M | -32.02M |
| EBITDA | -56.04M | -46.80M | -45.56M | -33.08M | -31.79M |
| EPS Basic | -2.45 | -1.91 | -1.78 | -1.58 | -1.68 |
| Normalized Basic EPS | -0.51 | -0.26 | -0.37 | -0.33 | -0.35 |
| EPS Diluted | -2.45 | -1.91 | -1.78 | -1.58 | -1.68 |
| Normalized Diluted EPS | -0.51 | -0.26 | -0.37 | -0.33 | -0.35 |
| Average Basic Shares Outstanding | 57.35M | 57.30M | 57.21M | 49.41M | 46.57M |
| Average Diluted Shares Outstanding | 19.12M | 19.10M | 19.07M | 16.47M | 15.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |